Divalproex Sodium
Product Images NDC 53808-0831

5 FDA label images from State Of Florida Doh Central Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 53808-0831). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Divalproex Sodium Extend-release Tablets, Usp 500 mg Bottle Label (Divalpoex Sod 500mg Mylan)

Divalproex Sodium Extend-release Tablets, Usp 500 mg Bottle Label (Divalpoex Sod 500mg Mylan)
Label for Divalproex Sodium extended-release (SOD/ER) 500 mg tablets. The label indicates prescription-only status and states it was packaged by the State of Florida DOH Central Pharmacy in Tallahassee, FL. A barcode and UPC code are visible on the label.*
FDA Label Image

Divalproex Structural Formula (Fd4949b2 1af2 4725 899f F54cc5cd2db6 01)

Divalproex Structural Formula (Fd4949b2 1af2 4725 899f F54cc5cd2db6 01)
Chemical structure diagram of the active ingredient Divalproex Sodium, showing the molecular arrangement and bonding of its components, including sodium ion representation and the structural formula of the valproate moieties.*
FDA Label Image

Proportion Of Patients Achieving Any Particular Level Of Improvement Was Consistently Higher For Valproate Than For Placebo (Fd4949b2 1af2 4725 899f F54cc5cd2db6 02)

Proportion Of Patients Achieving Any Particular Level Of Improvement Was Consistently Higher For Valproate Than For Placebo (Fd4949b2 1af2 4725 899f F54cc5cd2db6 02)
A cumulative distribution plot comparing percentage reduction in CPS rate between Divalproex Sodium Delayed-Release and placebo. The chart shows % reduction on the vertical axis and % of patients on the horizontal axis, illustrating greater improvement in the Divalproex Sodium group relative to placebo.*
FDA Label Image

Proportion Of Patients Achieving Any Particular Level Of Reduction Was Consistently Higher For High Dose Valproate Than For Low Dose Valproate (Fd4949b2 1af2 4725 899f F54cc5cd2db6 03)

Proportion Of Patients Achieving Any Particular Level Of Reduction Was Consistently Higher For High Dose Valproate Than For Low Dose Valproate (Fd4949b2 1af2 4725 899f F54cc5cd2db6 03)
A line graph depicting the percentage reduction in CPS rate for patients treated with high dose and low dose Divalproex Sodium delayed release. The x-axis represents the percentage of patients, while the y-axis shows the change in CPS rate from worsening to improvement, with a no-change baseline at 0%.*
FDA Label Image

Figure 3 Mean Reduction In 4-week Migraine Headache Rates (Fd4949b2 1af2 4725 899f F54cc5cd2db6 04)

Figure 3 Mean Reduction In 4-week Migraine Headache Rates (Fd4949b2 1af2 4725 899f F54cc5cd2db6 04)
A bar graph comparing the effect of Divalproex Sodium Extended-Release Tablets and placebo. It shows two bars, one labeled placebo with a value of 0.6 and the other labeled Divalproex Sodium Extended-Release Tablets with a higher value of 1.2, marked with an asterisk indicating statistical significance (p=0.006).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.